NCT04992013: Niraparib in Tumors Metastatic to the CNS

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: BRCA+, DNA damage repair mutations, ATM, ATR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least one lesion that can be accurately measured in at least one dimension as greater than or equal to 10 mm
Exclusions: Patients with prior treatment of a PARP inhibitor (e.g. Lynparza/olaparib)

Comments are closed.

Up ↑